Abstract:Title. Androgen Receptor Protein Degraders Patent Publication Number. WO 2020/142228 A1 Publication Date. July 09, 2020 Priority Application. US 62/788,005 Priority Date. January 03, 2019 Inventors.Wang, S.; Han, X.; Wang, C.; Qin, C.; Xiang, W.; Xu, T.; Yang, C. Assignee Company. The Regents of the University of Michigan [US/US]; Office of Technology Transfer, 1600 Huron Parkway, second Floor, Ann Arbor, MI 48109−2590 (US). Disease Area. Prostate cancer (PCa) Biological Target. Androgen receptor Summary. Androgens are a class of steroid hormones that consist of natural or synthetic steroid hormone derivatives of cholesterol, which play a role in the development and maintenance of male characteristics. They function primarily through androgen receptor (AR) signaling and are recognized as a key driver of prostate cancer (PCa) growth and survival. The AR is a 110 kDa protein with sequence homology that is shared with other nuclear hormone receptors in the superfamily such as the progesterone receptor (PR), estrogen receptor (ER), and glucocorticoid receptor (GR). Furthermore, the AR consists of four basic elements: the N-terminal domain, DNA binding domain, hinge region, and ligand binding domain (LBD). The centrally located DNA binding domain consists of two zinc finger domains that recognize a specific DNA sequence and is the most highly conserved region. Whereas, the LBD forms the ligand-binding pocket that contains ligand-dependent activation function 2 (AF-2) and mediates interactions between the AR, heat shock proteins, and motifs located within the N-terminal domain. PCa remains themost common cancer and the second leading cause of cancer-related deaths inmen. However, if detected early the current arsenal of therapeutic options provide a promising chance for long-term survival, though ∼40% of patients will develop castration-resistant PCa. Androgen deprivation therapy (ADT) remains the primary treatment regimen for patients who demonstrate biochemical relapse and those that are challenged with locally advanced or metastatic disease. In some cases, the disease ultimately progresses to a lethal form despite castrating levels of testosterone and is termed metastatic castrationresistant prostate cancer (mCRPC). Most often, mCRPC is characterized by rising serum levels of prostate-specific antigen (PSA) after the restoration of the AR transcriptional activity. Consequently, the standard of care for patients with mCRPC after ADT treatment involves sustained AR inhibition that competitively bind the ligand-binding domain (LBD) of the AR or CYP17A1 inhibitors. Mutation in the AR LBD as well as active AR-splice variants that lack the LBD have been associated with primary and acquired resistance. Consequently, a new therapeutic approach is needed in the treatment of PCa and related diseases associated with the AR. The present Patent Highlight showcases heterobifunctional small molecules that are androgen receptor (AR) protein degraders useful for the treatment of a variety of diseases including prostate cancer. The Proteolysis Targeting Chimera (PROTAC) strategy consists of a heterobifunctional small molecule containing one ligand that binds to the target protein of interest (AR) and a second ligand for an E3 ligase system, tethered together by a chemical linker. Thus, AR degraders designed based upon the PROTAC concept may be effective for the treatment of CRPC when the disease becomes resistant to AR antagonists or to androgen synthesis inhibitors.

Androgen receptor inhibitors in treating prostate cancer

Recent Developments in Androgen Receptor Antagonists.

Recent Androgen Receptor Antagonists in Prostate Cancer

The Role of Androgen Receptor in Prostate Cancer

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

PROTACs Targeting Androgen Receptor Signaling: Potential Therapeutic Agents for Castration-Resistant Prostate Cancer

Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer.

Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer

A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives

Androgen Receptor Roles in Benign and Malignant Prostate Disease

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

Androgen receptor: what we know and what we expect in castration-resistant prostate cancer

Degradation of Androgen Receptor Through Small Molecules for Prostate Cancer

Androgen receptor modulators: a review of recent patents and reports (2012-2018)

Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Transcriptional Repression By Androgen Receptor: Roles In Castration-Resistant Prostate Cancer

The function and research progress of androgen receptors on the development of castra-tion -resistant prostate cancer